Maze Therapeutics (MAZE) EBT Margin (2024 - 2026)
Maze Therapeutics (MAZE) reported EBT Margin of 97.98% for Q1 2026, down 600.48% sequentially from 19.58% in Q4 2024.
Maze Therapeutics (MAZE) EBT Margin (2024 - 2026) Analysis & Trends
Maze Therapeutics (MAZE) has 2 years of EBT Margin data on file, last reported at 97.98% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin changed N/A year-over-year to 97.98%; the trailing twelve-month figure through Mar 2026 stood at 589.64% (down 55030.0% YoY), and the FY2024 full-year result was 356.02%, changed N/A from the prior year.
- EBT Margin declined to 97.98% in Q1 2026, from 19.58% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 938.55% in Q2 2024 to a low of 1001.24% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | -97.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.98% |
| Dec 31, 2024 | 19.58% |
| Sep 30, 2024 | -1,001.24% |
| Jun 30, 2024 | 938.55% |